european
medicines
agency
accepts
biogen
aducanumab
marketing
authorization
application
alzheimer
disease
approved
aducanumab
would
become
first
therapy
reduce
clinical
decline
alzheimer
disease
meaningfully
change
course
alzheimer
disease
cambridge
mass
tokyo
globe
newswire
biogen
nasdaq
biib
eisai
tokyo
japan
today
announced
european
medicines
agency
ema
confirmed
accepted
review
following
standard
timetable
marketing
authorization
application
maa
aducanumab
investigational
treatment
alzheimer
disease
clinical
data
patients
mild
cognitive
impairment
due
alzheimer
disease
mild
alzheimer
disease
demonstrate
treatment
aducanumab
resulted
removal
amyloid
beta
better
clinical
outcomes
approved
aducanumab
would
become
first
therapy
reduce
clinical
decline
patients
alzheimer
disease
alzheimer
disease
become
significant
growing
burden
societies
around
world
believe
aducanumab
represents
first
breakthrough
change
course
devastating
disease
said
michel
vounatsos
chief
executive
officer
biogen
committed
working
regulatory
authorities
worldwide
look
forward
european
medicines
agency
review
treatments
available
impact
progression
alzheimer
disease
addressing
underlying
disease
pathology
potential
aducanumab
may
hold
effectively
reduce
clinical
decline
brings
new
hope
people
families
living
devastating
disease
said
haruo
naito
chief
executive
officer
eisai
acceptance
marketing
authorization
application
european
union
important
milestone
work
towards
making
potential
treatment
available
around
aducanumab
also
review
food
drug
administration
priority
review
prescription
drug
user
fee
act
pdufa
action
date
march
aducanumab
aducanumab
investigational
human
monoclonal
antibody
studied
treatment
alzheimer
disease
based
clinical
data
patients
mild
cognitive
impairment
due
alzheimer
disease
mild
alzheimer
disease
aducanumab
potential
impact
underlying
disease
pathophysiology
slow
cognitive
functional
decline
provide
benefits
patients
ability
perform
activities
daily
living
including
conducting
personal
finances
performing
household
chores
cleaning
shopping
laundry
independently
traveling
home
approved
aducanumab
would
first
treatment
meaningfully
change
course
disease
individuals
living
alzheimer
biogen
licensed
aducanumab
neurimmune
collaborative
development
license
agreement
since
october
biogen
eisai
collaborated
development
commercialization
aducanumab
globally
emerge
engage
phase
multicenter
randomized
studies
designed
evaluate
efficacy
safety
aducanumab
primary
objective
studies
evaluate
efficacy
monthly
doses
aducanumab
compared
placebo
reducing
cognitive
functional
impairment
measured
changes
clinical
dementia
boxes
score
secondary
objectives
assess
effect
monthly
doses
aducanumab
compared
placebo
clinical
decline
measured
state
examination
mmse
alzheimer
disease
assessment
subscale
items
alzheimer
disease
cooperative
daily
living
inventory
mild
cognitive
impairment
version
alzheimer
disease
alzheimer
disease
progressive
neurological
condition
impairs
thinking
memory
independence
leading
premature
death
disease
currently
stopped
delayed
prevented
growing
global
health
crisis
affecting
living
disease
families
according
world
health
organization
tens
millions
people
worldwide
live
alzheimer
disease
number
grow
years
ahead
outpacing
healthcare
resources
needed
manage
costing
billions
dollars
alzheimer
disease
international
alzheimer
yearbook
estimates
approximately
million
people
eu
suffer
dementia
excluding
mild
cognitive
impairment
ad
suspected
represent
around
dementia
cases
alzheimer
disease
characterized
changes
brain
including
abnormal
accumulation
toxic
amyloid
beta
plaque
begins
approximately
years
patients
exhibit
symptoms
disease
mild
cognitive
impairment
due
alzheimer
disease
one
earliest
stages
disease
symptoms
start
visible
detected
diagnosed
current
research
efforts
focused
catching
treating
patients
early
possible
best
chance
slowing
stopping
progression
alzheimer
disease
biogen
biogen
mission
clear
pioneers
neuroscience
biogen
discovers
develops
delivers
worldwide
innovative
therapies
people
living
serious
neurological
neurodegenerative
diseases
well
related
therapeutic
adjacencies
one
world
first
global
biotechnology
companies
biogen
founded
charles
weissmann
heinz
schaller
kenneth
murray
nobel
prize
winners
walter
gilbert
phillip
sharp
today
biogen
leading
portfolio
medicines
treat
multiple
sclerosis
introduced
first
approved
treatment
spinal
muscular
atrophy
commercializes
biosimilars
advanced
biologics
focused
advancing
research
programs
multiple
sclerosis
neuroimmunology
alzheimer
disease
dementia
neuromuscular
disorders
movement
disorders
ophthalmology
immunology
neurocognitive
disorders
acute
neurology
pain
routinely
post
information
may
important
investors
website
follow
us
social
media
twitter
linkedin
facebook
youtube
eisai
eisai
leading
global
pharmaceutical
company
headquartered
japan
eisai
corporate
philosophy
based
human
health
care
hhc
concept
give
first
thought
patients
families
increase
benefits
health
care
provides
global
network
r
facilities
manufacturing
sites
marketing
subsidiaries
strive
realize
hhc
philosophy
delivering
innovative
products
target
diseases
high
unmet
medical
needs
particular
focus
strategic
areas
neurology
oncology
leveraging
experience
gained
development
marketing
treatment
alzheimer
disease
eisai
aims
establish
eisai
dementia
platform
eisai
plans
deliver
novel
benefits
living
dementia
families
constructing
dementia
ecosystem
collaborating
partners
medical
organizations
diagnostic
development
companies
research
organizations
addition
private
insurance
agencies
finance
industries
fitness
clubs
automobile
makers
retailers
care
facilities
information
eisai
please
visit
https
biogen
safe
harbor
news
release
contains
statements
including
statements
made
pursuant
safe
harbor
provisions
private
securities
litigation
reform
act
potential
regulatory
discussions
submissions
approvals
timing
thereof
potential
clinical
effects
aducanumab
potential
benefits
safety
efficacy
aducanumab
treatment
alzheimer
disease
anticipated
benefits
potential
biogen
collaboration
arrangements
eisai
potential
biogen
commercial
business
pipeline
programs
including
aducanumab
risks
uncertainties
associated
drug
development
commercialization
statements
may
identified
words
aim
anticipate
believe
could
estimate
expect
forecast
intend
may
plan
possible
potential
would
words
terms
similar
meaning
drug
development
commercialization
involve
high
degree
risk
small
number
research
development
programs
result
commercialization
product
results
early
stage
clinical
trials
may
indicative
full
results
results
later
stage
larger
scale
clinical
trials
ensure
regulatory
approval
place
undue
reliance
statements
scientific
data
presented
statements
involve
risks
uncertainties
could
cause
actual
results
differ
materially
reflected
statements
including
without
limitation
actual
timing
content
submissions
decisions
made
regulatory
authorities
regarding
aducanumab
regulatory
submissions
may
take
longer
difficult
complete
expected
regulatory
authorities
may
require
additional
information
studies
may
fail
refuse
approve
may
delay
approval
biogen
drug
candidates
including
aducanumab
unexpected
concerns
may
arise
additional
data
analysis
results
obtained
clinical
trials
occurrence
adverse
safety
events
risks
unexpected
costs
delays
risk
unexpected
hurdles
uncertainty
success
development
potential
commercialization
aducanumab
risks
relating
potential
launch
aducanumab
including
preparedness
healthcare
providers
treat
patients
ability
obtain
maintain
adequate
reimbursement
aducanumab
unexpected
difficulties
hurdles
failure
protect
enforce
biogen
data
intellectual
property
proprietary
rights
uncertainties
relating
intellectual
property
claims
challenges
product
liability
claims
third
party
collaboration
risks
direct
indirect
impacts
ongoing
pandemic
biogen
business
results
operations
financial
condition
foregoing
sets
forth
many
factors
could
cause
actual
results
differ
biogen
expectations
statement
investors
consider
cautionary
statement
well
risk
factors
identified
biogen
recent
annual
quarterly
report
reports
biogen
filed
securities
exchange
commission
statements
based
biogen
current
beliefs
expectations
speak
date
news
release
biogen
undertake
obligation
publicly
update
statements
whether
result
new
information
future
developments
otherwise
